1.A Case of Capecitabine and Cisplatin-induced Cutaneous Hyperpigmentation.
Sang Hyeon HWANG ; Ji Hye PARK ; Chong Won CHOI ; Ga Young LEE ; Won Serk KIM
Korean Journal of Dermatology 2014;52(3):210-212
No abstract available.
Cisplatin
;
Hyperpigmentation*
;
Capecitabine
2.Nasolacrimal Duct Stenosis after Oral Capecitabine Administration
Yeonji JANG ; Namju KIM ; Keun Wook LEE ; Ho Kyung CHOUNG ; Sang In KHWARG
Korean Journal of Ophthalmology 2019;33(1):95-96
No abstract available.
Capecitabine
;
Constriction, Pathologic
;
Nasolacrimal Duct
3.Cessation or dose reduction of Capecitabine due to Complications in Patients with Colon Cancer.
Journal of the Korean Society of Coloproctology 2010;26(4):240-240
No abstract available.
Capecitabine
;
Colon
;
Colonic Neoplasms
;
Deoxycytidine
;
Fluorouracil
;
Humans
4.Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients.
Yun Hwa JUNG ; Won Jik LEE ; Jae Ho BYEON ; In Kyu LEE ; Chi Wha HAN ; In Sook WOO
The Korean Journal of Internal Medicine 2017;32(5):926-929
No abstract available.
Administration, Metronomic
;
Aged*
;
Capecitabine*
;
Colorectal Neoplasms*
;
Drug Therapy*
;
Humans
5.Hand-foot Syndrome Due to Capecitabine.
Chong Won CHOI ; Chang Hun HUH
Korean Journal of Dermatology 2005;43(7):965-968
Hand-foot syndrome, also known as acral erythema, is a distinctive and relatively common toxic reaction due to some anticancer drugs. It is characterized by a painful erythema on the palms and soles during chemotherapy, which is often preceeded by paresthesia. We report two cases of hand-foot syndrome induced by capecitabine, which is a relatively brand-new oral anticancer agent. Hand-foot syndrome is one of the most common complications of capecitabine, and is on the increase. Therefore, dermatologists should be aware of it.
Drug Therapy
;
Erythema
;
Hand-Foot Syndrome*
;
Paresthesia
;
Capecitabine
6.XELOX ± Bevacizumab compared to FOLFOX4 ± Bevacizumab in first line metastatic colorectal cancer in a non-reimbursed health care system: A cost analysis.
Tan Jerry Y. ; Yacat Andrew A ; Sacdalan Dennis L.
Acta Medica Philippina 2015;49(2):64-67
INTRODUCTION: XELOX is non-inferior to FOLFOX-4 as a first-line treatment for metastatic colorectal cancer. This study compares the costs associated with XEL0X+/-bevacizumab versus FOLFOX4+/-bevacizumab in a non-reimbursed, out of pocket Philippine health care system.
METHODS: This is a cost-minimization analysis using Philippine General Hospital as base case and a typical Filipino patient of 60 kg with BSA 1.66. The outcome data were derived from the N016966 trial. These included the drugs capecitabine, 5-fluorouracil, oxaliplatin, and bevacizumab (BEV); chemotherapy cycles and corresponding hospital admission for each regimen; resources associated with treatment of adverse events such hospital days, ambulatory consultations, concomitant
medication, and central venous line insertion/removal, with costs and charges based on the local setting.
RESULTS: Highest cost (direct and/or indirect) was for FOLFOX4+BEV, followed by XEL0X+BEV, FOLFOX4, and then XELOX. The use of XELOX resulted in a cost saving of PhP 158,642 per patient compared with FOLFOX4. The use of XEL0X+BEV resulted in a cost saving of PhP 186,144 per patient compared with FOLFOX4+BEV.
CONCLUSION: XEL0X+/-BEV is less costly than FOLFOX4-F/-BEV in an out-of-pocket Philippine tertiary hospital setting from the patient's perspective.
Xelox ; Folfox ; Colorectal Neoplasms ; Capecitabine ; Fluorouracil ; Oxaliplatin ; Bevacizumab
7.Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy.
Jina YUN ; Kyoung Mee KIM ; Seung Tae KIM ; Jung Hoon KIM ; Jung A KIM ; Jee Hyun KONG ; Soo Hyeon LEE ; Young Woong WON ; Jong Mu SUN ; Jeeyun LEE ; Se Hoon PARK ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Won Ki KANG
Cancer Research and Treatment 2010;42(2):101-106
PURPOSE: The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy. MATERIALS AND METHODS: A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei. RESULTS: Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%). CONCLUSION: In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.
Cell Nucleus
;
Cisplatin
;
Deoxycytidine
;
Epirubicin
;
Fluorouracil
;
Humans
;
Stomach Neoplasms
;
Survival Rate
;
Capecitabine
8.Overview of Radiation Therapy for Treating Rectal Cancer.
Bong Hyeon KYE ; Hyeon Min CHO
Annals of Coloproctology 2014;30(4):165-174
A major outcome of importance for rectal cancer is local control. Parallel to improvements in surgical technique, adjuvant therapy regimens have been tested in clinical trials in an effort to reduce the local recurrence rate. Nowadays, the local recurrence rate has been reduced because of both good surgical techniques and the addition of radiotherapy. Based on recent reports in the literature, preoperative chemoradiotherapy is now considered the standard of care for patients with stages II and III rectal cancer. Also, short-course radiotherapy appears to provide effective local control and the same overall survival as more long-course chemoradiotherapy schedules and, therefore, may be an appropriate choice in some situations. Capecitabine is an acceptable alternative to infusion fluorouracil in those patients who are able to manage the responsibilities inherent in self-administered, oral chemotherapy. However, concurrent administration of oxaliplatin and radiotherapy is not recommended at this time. Radiation therapy has long been considered an important adjunct in the treatment of rectal cancer. Although no prospective data exist for several issues, we hope that in the near future, patients with rectal cancer can be treated by using the best combination of surgery, radiation therapy, and chemotherapy in near future.
Appointments and Schedules
;
Chemoradiotherapy
;
Drug Therapy
;
Fluorouracil
;
Hope
;
Humans
;
Radiotherapy
;
Rectal Neoplasms*
;
Recurrence
;
Standard of Care
;
Capecitabine
9.Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer.
Chi Hwan CHOI ; Won Dong KIM ; Sang Jeon LEE ; Woo Yoon PARK
Radiation Oncology Journal 2012;30(3):99-107
PURPOSE: The aim of this study was to identify clinical predictive factors for tumor response after preoperative chemoradiotherapy (CRT) in rectal cancer. MATERIALS AND METHODS: The study involved 51 patients who underwent preoperative CRT followed by surgery between January 2005 and February 2012. Radiotherapy was delivered to the whole pelvis at a dose of 45 Gy in 25 fractions, followed by a boost of 5.4 Gy in 3 fractions to the primary tumor with 5 fractions per week. Three different chemotherapy regimens were used (5-fluorouracil and leucovorin, capecitabine, or tegafur/uracil). Tumor responses to preoperative CRT were assessed in terms of tumor downstaging and pathologic complete response (ypCR). Statistical analyses were performed to identify clinical factors associated with pathologic tumor response. RESULTS: Tumor downstaging was observed in 28 patients (54.9%), whereas ypCR was observed in 6 patients (11.8%). Multivariate analysis found that predictors of downstaging was pretreatment relative lymphocyte count (p = 0.023) and that none of clinical factors was significantly associated with ypCR. CONCLUSION: Pretreatment relative lymphocyte count (%) has a significant impact on the pathologic tumor response (tumor downstaging) after preoperative CRT for locally advanced rectal cancer. Enhancement of lymphocyte-mediated immune reactions may improve the effect of preoperative CRT for rectal cancer.
Chemoradiotherapy
;
Deoxycytidine
;
Fluorouracil
;
Humans
;
Leucovorin
;
Lymphocyte Count
;
Multivariate Analysis
;
Pelvis
;
Rectal Neoplasms
;
Capecitabine
10.Hand-foot Syndrome Following Capecitabine (Xeloda(R)) Monotherapy for Colorectal Cancer.
Soon Do PARK ; Kil Yeon LEE ; Sun Jin PARK ; Suk Hwan LEE ; Sang Mok LEE
Journal of the Korean Society of Coloproctology 2009;25(4):227-233
PURPOSE: Capecitabine (Xeloda(R)), which is a systemic prodrug of 5-fluorouracil, can be used in oral formulation for treatment of advanced colorectal cancer as a 1st line or an alternative modality to I.V. 5-fluorouracil-based chemotherapy. One of the most common side effects of this drug is hand-foot syndrome (HFS), palmar-plantar erythrodysesthesia syndrome. We planned this study to clarify the incidence and the clinical course of severe hand-foot syndrome (WHO classification, grade 3 or 4) following capecitabine monotherapy for adjuvant treatment of colorectal cancer. METHODS: From August 2006 to August 2008, 45 colorectal cancer patients were treated with capecitabine, 1,250 mg/m2, orally administered twice daily for 2 wk, followed by 1 wk of rest, given as 3-wk cycles. Seven of them discontinued the drug within 3rd cycle due to poor performance status, gastrointestinal troubles, or other causes. We retrospectively analyzed the remaining 38 patients' medical records and defined the incidence and the clinical course of HFS. RESULTS: Of the 38 patients, 17 (44.7%) suffered severe HFS after capecitabine monotherapy. Of those 17, 5 (29.4%) had severe symptoms after the 1st chemotherapy cycle, and 14 patients (82.4%) had severe symptoms within the 4th cycle. Three of the 14 female and 14 of the 24 male patients complained of severe HFS, showing a statistical male predominance (P=0.043). Eventually, we had to decrease capecitabine to 75% of the daily dose in 12 patients and to 50% in one patient, and to discontinue its use in 4 patients. CONCLUSION: Capecitabine monotherapy very frequently provokes severe HFS, especially in the early cycles of chemotherapy and in males.
Capecitabine
;
Colorectal Neoplasms
;
Deoxycytidine
;
Female
;
Fluorouracil
;
Hand-Foot Syndrome
;
Humans
;
Incidence
;
Male
;
Medical Records
;
Retrospective Studies